Sangamo Therapeutics Q3 EPS $(0.59) Misses $(0.32) Estimate, Sales $9.40M Miss $10.40M Estimate
Portfolio Pulse from bharat@benzinga.com
Sangamo Therapeutics reported Q3 losses of $0.59 per share, missing the analyst consensus estimate of $0.32 by 84.37%. The company also reported quarterly sales of $9.40 million, missing the analyst consensus estimate of $10.40 million by 9.63%. This represents a 73.53% decrease in earnings and a 64.48% decrease in sales compared to the same period last year.
November 01, 2023 | 8:23 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Sangamo Therapeutics' Q3 results missed estimates, with a larger than expected loss per share and lower sales. This could negatively impact the company's stock in the short term.
Sangamo Therapeutics reported larger than expected losses and lower sales for Q3. This underperformance compared to estimates and the significant decrease from last year's figures could lead to a negative reaction from investors, potentially driving the stock price down in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100